Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (487)	4/10/2003 2:06:11 PM
From: tom pope	of 897

As Rick was saying........... Briefing: 13:07 ET OSIP OSI Pharm gives Tarceva development program update (14.27 -1.62) -- Update -- Announces that the independent Data Monitoring Committee (DMC) recommended that Tarceva study treatment be discontinued at the time of disease progression or the start of second-line chemotherapy or radiation due to a safety signal. No specific details were given by the DMC, but they did not recommend any additional safety monitoring guidelines for the ongoing clinical program; the change does not impact other programs and is not expected to impact the timeline for top-line data results for either the TRIBUTE study or the other front-line Tarceva combination chemotherapy study, TALENT, being conducted by Roche. Data is anticipated in 2H03

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next